User:Mac/Agenda: Difference between revisions
< User:Mac
Jump to navigation
Jump to search
No edit summary |
|||
| Line 11: | Line 11: | ||
* read chapter 20, ''Gene patents: from discovery to invention'' from ''Gene Patents and Collaborative Licensing Models'' | * read chapter 20, ''Gene patents: from discovery to invention'' from ''Gene Patents and Collaborative Licensing Models'' | ||
** add the above to the bibliography | ** add the above to the bibliography | ||
** [[Diagnostic_Kits/Genes_and_ingenuity:_gene_patenting_and_human_health_report|Australian Law Reform Commission. Genes and ingenuity: gene patenting and human health report. (2004) pp. 678]] | |||
** [[/Diagnostic_Kits/Patenting_and_licensing_in_genetic_testing:_recommendations_of_the_European_Society_of_Human_Genetics|Aymé et al. Patenting and licensing in genetic testing: recommendations of the European Society of Human Genetics. European Journal of Human Genetics (2008) vol. 16 Suppl 1 pp. S10-9]] | |||
* read a bunch of other papers I printed | * read a bunch of other papers I printed | ||
* compress the findings of the SACGHS report, European report, and Australian report in an executive summary in new section | * compress the findings of the SACGHS report, European report, and Australian report in an executive summary in new section | ||
| Line 17: | Line 20: | ||
** like pharmacogenetics vs. pharmacogenomics? | ** like pharmacogenetics vs. pharmacogenomics? | ||
* visit http://www.egappreviews.org/workingrp/topics_consider.htm | * visit http://www.egappreviews.org/workingrp/topics_consider.htm | ||
* visit http://www.cdc.gov/genomics/gtesting/ | * visit http://www.cdc.gov/genomics/gtesting/ | ||
== 11 Jan 2010 == | == 11 Jan 2010 == | ||
Latest revision as of 13:53, 27 January 2010
18 Jan 2010
- track down a ton of papers from the bibliographies of Legal uncertainty in the area of genetic diagnostic testing and Genome patents and personalized medicine - what lies ahead?
- add the above to the bibliography
- read chapter 20, Gene patents: from discovery to invention from Gene Patents and Collaborative Licensing Models
- add the above to the bibliography
- Australian Law Reform Commission. Genes and ingenuity: gene patenting and human health report. (2004) pp. 678
- Aymé et al. Patenting and licensing in genetic testing: recommendations of the European Society of Human Genetics. European Journal of Human Genetics (2008) vol. 16 Suppl 1 pp. S10-9
- read a bunch of other papers I printed
- compress the findings of the SACGHS report, European report, and Australian report in an executive summary in new section
- make sure the definition of genetic and genomic tests in the glossary is consistant
- incorporate definition from SACGHS report; also "Where there's a web, there's a way" paper
- like pharmacogenetics vs. pharmacogenomics?
- visit http://www.egappreviews.org/workingrp/topics_consider.htm
- visit http://www.cdc.gov/genomics/gtesting/
11 Jan 2010
- Got Misha's Feedback
- read this: College of American Pathologists POET report on IVDMIAs
- And this: market report w/r/t multivariate testing (at least the table of contents)
- Get Annual Reports from key companies listed; summarize
- Add papers about GDx reference materials from Journal of Molecular Diagnostics
- add profiles of major Personal Genomics companies to Overall Picture of Kits Sector
2 Dec 2009 TODO
- add GDx / PGx from SACGHS appendix and PGx paper to the case studies (~15?)
- Add OTC genetic tests to the list
- move to no.2, overall picture of kits
- write 1 paragraph / section of paper outline
- centralize answers to "do patents harm researchers?"
complete field definition- 1st draftcomplete data, narratives, tools defn, build off of Ford report sectionget basic market stats / picture (just GDx)- partial; just national ref labs
- read last chapter's of Gene Cartels
read SACGHS Report final draft- back up the following statements with data (in particular, "But the vast majority of gene patents are obtained by universities and unlicensed, or by companies and unprosecuted.")
Duke team, Luigi interview
- come up w/ questions
- position on IVDMIAs
- use interview framework from EM
Identify people to ask about IVDMIA tests
- look at federal docket of comments in response to draft guideline
- ask the 5 OTC companies in interview